Imidazoline I2 receptor density increases with the malignancy of human gliomas
Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I2 receptors are principally expressed on glial cells. Objective: To investigate the feasibility of using the measurement of imidazoline I2 receptor expression to differentiate glial tumours from...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2004-05, Vol.75 (5), p.785-787 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 787 |
|---|---|
| container_issue | 5 |
| container_start_page | 785 |
| container_title | Journal of neurology, neurosurgery and psychiatry |
| container_volume | 75 |
| creator | Callado, L F Martín-Gómez, J I Ruiz, J Garibi, J M Meana, J J |
| description | Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I2 receptors are principally expressed on glial cells. Objective: To investigate the feasibility of using the measurement of imidazoline I2 receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. Methods: The specific binding of [3H]idazoxan to imidazoline I2 receptors was measured in homogenates from human gliomas of different grades. Results: The density of imidazoline I2 receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. Conclusion: These results suggest that the density of imidazoline I2 receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas. |
| doi_str_mv | 10.1136/jnnp.2003.020446 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1763557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4023780071</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4246-e1b2b0fe043c48ffab20fb64a1690806bb540f77394b6db617e1b31df726a0dd3</originalsourceid><addsrcrecordid>eNqNkc1vEzEQxS1ERUPhztES4gQbxh_r3VyQUAQlUluQgCo3y961E4ddO9gbIPz1dbRRox6QmMsc5vfejP0QekFgSggTbzfeb6cUgE2BAufiEZoQLuqCMVg-RhMASgsGJZyjpylt4FD17Ak6JyXMoKz5BN0seteqv6Fz3uAFxdE0ZjuEiFvjkxv22PkmGpVMwr_dsMbD2uBedW7llW_2OFi83vXK41XnQq_SM3RmVZfM82O_QN8_fvg2_1Rcfb5czN9fFZpTLgpDNNVgDXDW8NpapSlYLbgiYgY1CK1LDraq2Ixr0WpBqqxgpLUVFQrall2gd6Pvdqd70zbGD1F1chtdr-JeBuXkw4l3a7kKvySpBCvLKhu8PBrE8HNn0iA3YRd9vjkjNaGMg6CZgpFqYkgpGnu_gYA8JCAPCchDAnJMIEteHY1ValRnY_4nl066vJtyUmeuGDmXBvPnfq7iDykqVpXy5nYuvywvv97CspbXmX898rrf_M8Vb0706WX_wu8AJnGwrA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781234062</pqid></control><display><type>article</type><title>Imidazoline I2 receptor density increases with the malignancy of human gliomas</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Callado, L F ; Martín-Gómez, J I ; Ruiz, J ; Garibi, J M ; Meana, J J</creator><creatorcontrib>Callado, L F ; Martín-Gómez, J I ; Ruiz, J ; Garibi, J M ; Meana, J J</creatorcontrib><description>Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I2 receptors are principally expressed on glial cells. Objective: To investigate the feasibility of using the measurement of imidazoline I2 receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. Methods: The specific binding of [3H]idazoxan to imidazoline I2 receptors was measured in homogenates from human gliomas of different grades. Results: The density of imidazoline I2 receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. Conclusion: These results suggest that the density of imidazoline I2 receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp.2003.020446</identifier><identifier>PMID: 15090584</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Analysis of covariance ; Biological and medical sciences ; Brain cancer ; GFAP ; GFAP, glial fibrillary acidic protein ; glial fibrillary acidic protein ; gliomas ; human brain ; i.p ; i.p., intraperitoneally ; I2 imidazoline receptor ; I2-IR ; imidazoline I2 receptors ; imidazoline receptor ; intraperitoneally ; IR, I ; Medical sciences ; Membranes ; Neurology ; Patients ; PET ; PET, positron emission tomography ; positron emission tomography ; Proteins ; Short Report ; Short reports ; Surgery ; Tumors</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 2004-05, Vol.75 (5), p.785-787</ispartof><rights>Copyright 2004 Journal of Neurology Neurosurgery and Psychiatry</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Journal of Neurology Neurosurgery and Psychiatry2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4246-e1b2b0fe043c48ffab20fb64a1690806bb540f77394b6db617e1b31df726a0dd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1763557/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1763557/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15732418$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Callado, L F</creatorcontrib><creatorcontrib>Martín-Gómez, J I</creatorcontrib><creatorcontrib>Ruiz, J</creatorcontrib><creatorcontrib>Garibi, J M</creatorcontrib><creatorcontrib>Meana, J J</creatorcontrib><title>Imidazoline I2 receptor density increases with the malignancy of human gliomas</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I2 receptors are principally expressed on glial cells. Objective: To investigate the feasibility of using the measurement of imidazoline I2 receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. Methods: The specific binding of [3H]idazoxan to imidazoline I2 receptors was measured in homogenates from human gliomas of different grades. Results: The density of imidazoline I2 receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. Conclusion: These results suggest that the density of imidazoline I2 receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.</description><subject>Analysis of covariance</subject><subject>Biological and medical sciences</subject><subject>Brain cancer</subject><subject>GFAP</subject><subject>GFAP, glial fibrillary acidic protein</subject><subject>glial fibrillary acidic protein</subject><subject>gliomas</subject><subject>human brain</subject><subject>i.p</subject><subject>i.p., intraperitoneally</subject><subject>I2 imidazoline receptor</subject><subject>I2-IR</subject><subject>imidazoline I2 receptors</subject><subject>imidazoline receptor</subject><subject>intraperitoneally</subject><subject>IR, I</subject><subject>Medical sciences</subject><subject>Membranes</subject><subject>Neurology</subject><subject>Patients</subject><subject>PET</subject><subject>PET, positron emission tomography</subject><subject>positron emission tomography</subject><subject>Proteins</subject><subject>Short Report</subject><subject>Short reports</subject><subject>Surgery</subject><subject>Tumors</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNkc1vEzEQxS1ERUPhztES4gQbxh_r3VyQUAQlUluQgCo3y961E4ddO9gbIPz1dbRRox6QmMsc5vfejP0QekFgSggTbzfeb6cUgE2BAufiEZoQLuqCMVg-RhMASgsGJZyjpylt4FD17Ak6JyXMoKz5BN0seteqv6Fz3uAFxdE0ZjuEiFvjkxv22PkmGpVMwr_dsMbD2uBedW7llW_2OFi83vXK41XnQq_SM3RmVZfM82O_QN8_fvg2_1Rcfb5czN9fFZpTLgpDNNVgDXDW8NpapSlYLbgiYgY1CK1LDraq2Ixr0WpBqqxgpLUVFQrall2gd6Pvdqd70zbGD1F1chtdr-JeBuXkw4l3a7kKvySpBCvLKhu8PBrE8HNn0iA3YRd9vjkjNaGMg6CZgpFqYkgpGnu_gYA8JCAPCchDAnJMIEteHY1ValRnY_4nl066vJtyUmeuGDmXBvPnfq7iDykqVpXy5nYuvywvv97CspbXmX898rrf_M8Vb0706WX_wu8AJnGwrA</recordid><startdate>200405</startdate><enddate>200405</enddate><creator>Callado, L F</creator><creator>Martín-Gómez, J I</creator><creator>Ruiz, J</creator><creator>Garibi, J M</creator><creator>Meana, J J</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>200405</creationdate><title>Imidazoline I2 receptor density increases with the malignancy of human gliomas</title><author>Callado, L F ; Martín-Gómez, J I ; Ruiz, J ; Garibi, J M ; Meana, J J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4246-e1b2b0fe043c48ffab20fb64a1690806bb540f77394b6db617e1b31df726a0dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Analysis of covariance</topic><topic>Biological and medical sciences</topic><topic>Brain cancer</topic><topic>GFAP</topic><topic>GFAP, glial fibrillary acidic protein</topic><topic>glial fibrillary acidic protein</topic><topic>gliomas</topic><topic>human brain</topic><topic>i.p</topic><topic>i.p., intraperitoneally</topic><topic>I2 imidazoline receptor</topic><topic>I2-IR</topic><topic>imidazoline I2 receptors</topic><topic>imidazoline receptor</topic><topic>intraperitoneally</topic><topic>IR, I</topic><topic>Medical sciences</topic><topic>Membranes</topic><topic>Neurology</topic><topic>Patients</topic><topic>PET</topic><topic>PET, positron emission tomography</topic><topic>positron emission tomography</topic><topic>Proteins</topic><topic>Short Report</topic><topic>Short reports</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Callado, L F</creatorcontrib><creatorcontrib>Martín-Gómez, J I</creatorcontrib><creatorcontrib>Ruiz, J</creatorcontrib><creatorcontrib>Garibi, J M</creatorcontrib><creatorcontrib>Meana, J J</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Callado, L F</au><au>Martín-Gómez, J I</au><au>Ruiz, J</au><au>Garibi, J M</au><au>Meana, J J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imidazoline I2 receptor density increases with the malignancy of human gliomas</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><stitle>J Neurol Neurosurg Psychiatry</stitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>2004-05</date><risdate>2004</risdate><volume>75</volume><issue>5</issue><spage>785</spage><epage>787</epage><pages>785-787</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I2 receptors are principally expressed on glial cells. Objective: To investigate the feasibility of using the measurement of imidazoline I2 receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. Methods: The specific binding of [3H]idazoxan to imidazoline I2 receptors was measured in homogenates from human gliomas of different grades. Results: The density of imidazoline I2 receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. Conclusion: These results suggest that the density of imidazoline I2 receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><pmid>15090584</pmid><doi>10.1136/jnnp.2003.020446</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3050 |
| ispartof | Journal of neurology, neurosurgery and psychiatry, 2004-05, Vol.75 (5), p.785-787 |
| issn | 0022-3050 1468-330X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1763557 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Analysis of covariance Biological and medical sciences Brain cancer GFAP GFAP, glial fibrillary acidic protein glial fibrillary acidic protein gliomas human brain i.p i.p., intraperitoneally I2 imidazoline receptor I2-IR imidazoline I2 receptors imidazoline receptor intraperitoneally IR, I Medical sciences Membranes Neurology Patients PET PET, positron emission tomography positron emission tomography Proteins Short Report Short reports Surgery Tumors |
| title | Imidazoline I2 receptor density increases with the malignancy of human gliomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A59%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imidazoline%20I2%20receptor%20density%20increases%20with%20the%20malignancy%20of%20human%20gliomas&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Callado,%20L%20F&rft.date=2004-05&rft.volume=75&rft.issue=5&rft.spage=785&rft.epage=787&rft.pages=785-787&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp.2003.020446&rft_dat=%3Cproquest_pubme%3E4023780071%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781234062&rft_id=info:pmid/15090584&rfr_iscdi=true |